Research progress in immunotherapy for nasopharyngeal carcinoma
Nasopharyngeal carcinoma(NPC)is the most common malignant tumor in head and neck region.In recent years,breakthrough progress has been made in immune checkpoint inhibitors(ICIs)based on programmed death-1/programmed death ligand-1(PD-1/PD-L1)blockade,and PD-1 inhibitors have been approved for the treatment of recurrent and/or metastatic NPC.At present,PD-1 immune checkpoint inhibitors have become the main method of NPC immunotherapy,and other immunotherapies include tumor vaccines,cytokines,therapeutic antibodies,molecular targeted therapy,etc.NPC immunotherapy improves the body's immunity,reduces the side effects of therapy,and improves quality of life for patients.Many clinical studies have investigated the safety and effectiveness of immunotherapy in the therapy of advanced NPC.Significant progress has been made in the immunotherapy of NPC,and multiple clinical studies on immunotherapy have achieved success in terminal NPC.Based on literature research,this article reviews the principles,main methods,and existing problems of NPC immunotherapy from three aspects:tumor immunotherapy,NPC immunotherapy methods,and the shortcomings of NPC immunotherapy.The aim of this article is to provide the best plan for immunotherapy of NPC.
NETL
NSTL
万方数据
